Biocept and Plus Therapeutics sign licensing deal for CNSide technology
Biocept, Inc. and Plus Therapeutics, Inc. have entered a non-exclusive licensing agreement expanding their existing laboratory services. Under this new deal, Plus will pay Biocept an upfront fee of $150,000 in stock and $6,000 per cerebrospinal fluid (CSF) tumor cell enumeration analysis. Once the technology transfer is complete, Plus will pay $300,000 plus fees starting […]